BACKGROUND: The bone morphogenetic proteins (BMP) are phytogenetically conserved proteins, which are essential for embryonic development. Bone morphogenetic protein-2 (BMP-2) was recently shown to be expressed in a small sample of lung carcinomas. Studies have suggested that BMP-2 may enhance tumor growth. The present study examined which BMP family members are expressed in non-small cell lung carcinomas (NSCLC). Furthermore, the frequency of BMP-2 overexpression and the types of lung carcinomas expressing BMP-2 were determined. METHODS: Tissue samples were obtained from the operating room and frozen in liquid nitrogen. Samples included metastatic NSCLC, benign lung tumors, adenocarcinoma, squamous cell carcinoma, bronchioloalveolar, and neuroendocrine carcinomas. Paired normal lung tissues served as the controls. The BMP-2, BMP-4, BMP-6, BMP-7, and growth differentiation factor 5 (GDF-5) expressions were examined by Western blot analysis. RESULTS: The BMP-4, BMP-6, BMP-7, and GDF-5 were infrequently expressed in NSCLC. The BMP-2 was expressed in 41 of 42 NSCLC with minimal expression in normal lung tissue; BMP-2 was expressed 17 fold higher than that of normal lung tissue. The BMP-2 was over-expressed in all subtypes of NSCLC, including neuroendocrine carcinomas. The BMP-2 expression was similar between squamous cell carcinomas and adenocarcinomas; however, bronchioloalveolar carcinomas tended to have a lower level of expression. The BMP-2 was not significantly expressed in benign lung tumors. CONCLUSIONS: Bone morphogenetic protein-2 is the predominant family member expressed in NSCLC. The BMP-2 is overexpressed in the majority of human lung carcinomas independent of cell type.
BACKGROUND: The bone morphogenetic proteins (BMP) are phytogenetically conserved proteins, which are essential for embryonic development. Bone morphogenetic protein-2 (BMP-2) was recently shown to be expressed in a small sample of lung carcinomas. Studies have suggested that BMP-2 may enhance tumor growth. The present study examined which BMP family members are expressed in non-small cell lung carcinomas (NSCLC). Furthermore, the frequency of BMP-2 overexpression and the types of lung carcinomas expressing BMP-2 were determined. METHODS: Tissue samples were obtained from the operating room and frozen in liquid nitrogen. Samples included metastatic NSCLC, benign lung tumors, adenocarcinoma, squamous cell carcinoma, bronchioloalveolar, and neuroendocrine carcinomas. Paired normal lung tissues served as the controls. The BMP-2, BMP-4, BMP-6, BMP-7, and growth differentiation factor 5 (GDF-5) expressions were examined by Western blot analysis. RESULTS: The BMP-4, BMP-6, BMP-7, and GDF-5 were infrequently expressed in NSCLC. The BMP-2 was expressed in 41 of 42 NSCLC with minimal expression in normal lung tissue; BMP-2 was expressed 17 fold higher than that of normal lung tissue. The BMP-2 was over-expressed in all subtypes of NSCLC, including neuroendocrine carcinomas. The BMP-2 expression was similar between squamous cell carcinomas and adenocarcinomas; however, bronchioloalveolar carcinomas tended to have a lower level of expression. The BMP-2 was not significantly expressed in benign lung tumors. CONCLUSIONS:Bone morphogenetic protein-2 is the predominant family member expressed in NSCLC. The BMP-2 is overexpressed in the majority of humanlung carcinomas independent of cell type.
Authors: Moubin Lin; David J Stewart; Margaret R Spitz; Michelle A T Hildebrandt; Charles Lu; Jie Lin; Jian Gu; Maosheng Huang; Scott M Lippman; Xifeng Wu Journal: Carcinogenesis Date: 2011-04-22 Impact factor: 4.944
Authors: Jenna H Newman; David J Augeri; Rachel NeMoyer; Jyoti Malhotra; Elaine Langenfeld; Charles B Chesson; Natalie S Dobias; Michael J Lee; Saeed Tarabichi; Sachin R Jhawar; Praveen K Bommareddy; Sh'Rae Marshall; Evita T Sadimin; John E Kerrigan; Michael Goedken; Christine Minerowicz; Salma K Jabbour; Shengguo Li; Mary O Carayannopolous; Andrew Zloza; John Langenfeld Journal: Oncogene Date: 2018-04-06 Impact factor: 9.867
Authors: Anastasios Fotinos; Narayani Nagarajan; Adriano S Martins; David T Fritz; Diane Garsetti; Annette T Lee; Charles C Hong; Melissa B Rogers Journal: Anticancer Res Date: 2014-05 Impact factor: 2.480
Authors: Chandramohan Kattamuri; David M Luedeke; Kristof Nolan; Scott A Rankin; Kenneth D Greis; Aaron M Zorn; Thomas B Thompson Journal: J Mol Biol Date: 2012-10-09 Impact factor: 5.469
Authors: Chanèle Cyr-Depauw; Jason J Northey; Sébastien Tabariès; Matthew G Annis; Zhifeng Dong; Sean Cory; Michael Hallett; Jonathan P Rennhack; Eran R Andrechek; Peter M Siegel Journal: Mol Cell Biol Date: 2016-05-02 Impact factor: 4.272
Authors: Joon Won Yoon; Richard Gilbertson; Stephen Iannaccone; Philip Iannaccone; David Walterhouse Journal: Int J Cancer Date: 2009-01-01 Impact factor: 7.396
Authors: Susanne Steinert; Torsten C Kroll; Isabel Taubert; Larissa Pusch; Peter Hortschansky; Klaus Höffken; Stefan Wölfl; Joachim H Clement Journal: J Cancer Res Clin Oncol Date: 2008-04-30 Impact factor: 4.553